+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Benign Prostatic Hypertrophy Medication Market - Global Forecast 2025-2030- Product Image
Benign Prostatic Hypertrophy Medication Market - Global Forecast 2025-2030- Product Image
Sale

Benign Prostatic Hypertrophy Medication Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6080410
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

An In-Depth Exploration of Benign Prostatic Hyperplasia Medication Landscape Highlighting Trends Patient Outcomes and Strategic Considerations

Benign prostatic hyperplasia remains one of the most common urological conditions affecting aging male populations worldwide. Characterized by the nonmalignant enlargement of the prostate gland, the condition leads to bothersome lower urinary tract symptoms that can significantly impair quality of life. While surgical interventions have long been a mainstay of treatment, pharmacotherapy continues to evolve as a preferred first-line approach due to its noninvasive nature and capacity for symptom management.

Over the past decades, advancements in pharmacological science have yielded a suite of therapeutic options, from 5-alpha reductase inhibitors to alpha blockers and combination regimens that optimize efficacy and safety. As patients and clinicians demand more personalized, outcome-driven care, stakeholders across the value chain-from manufacturers to providers and payers-must understand the interplay of clinical practice guidelines, regulatory policies, and patient preferences. This report delivers a comprehensive introduction to the current landscape, setting the stage for a deeper exploration of transformative shifts, tariff impacts, segmentation insights, regional nuances, and strategic imperatives.

Emerging Disruptions and Pioneering Innovations Reshaping the Treatment of Benign Prostatic Hyperplasia Across Clinical Practice and Patient Engagement

The treatment landscape for benign prostatic hyperplasia is undergoing a profound evolution driven by technological innovation and shifting patient expectations. Digital health platforms now facilitate remote monitoring of urinary symptoms, enabling more frequent patient-provider interactions without in-person visits. Telemedicine consultations have streamlined diagnostic workflows and adherence monitoring, particularly among older adults who face mobility challenges. Concurrently, the integration of wearable sensor data into clinical decision making has begun to inform more precise dosing regimens, reducing adverse effects while optimizing symptomatic relief.

Pharmaceutical innovation is likewise accelerating through the exploration of novel delivery systems and fixed-dose combinations. Innovations such as sustained-release formulations of alpha blockers and dual-mechanism capsules enhance convenience and support adherence over extended treatment horizons. Meanwhile, next-generation 5-alpha reductase inhibitors are being evaluated for improved selectivity and tolerability profiles. These developments reflect a broader industry shift toward patient-centric care models, where individualized therapy selections and digital support services converge to deliver better outcomes.

Assessing the Cumulative Consequences of Newly Imposed United States Tariffs on Pharmaceutical Supply Chains in Benign Prostatic Hyperplasia Therapies

In 2025, newly imposed United States tariffs have introduced a fresh layer of complexity to the benign prostatic hyperplasia medication supply chain. Many active pharmaceutical ingredients and intermediate compounds utilized in the production of 5-alpha reductase inhibitors and alpha blockers originate from global suppliers in India and Europe. The escalated duty rates have transmitted cost pressures upstream, forcing manufacturers to reassess sourcing strategies and negotiate revised supply contracts.

As a result, several industry leaders have initiated nearshoring efforts, exploring domestic API production partnerships to mitigate tariff exposure. These transitions require careful regulatory planning, as FDA approvals for new facilities can extend timelines and capital expenditures. At the same time, companies dependent on imported branded and generic formulations face inventory management challenges that may create intermittent shortages or price adjustments for end users. To navigate this environment, agile procurement teams are leveraging multi-sourcing agreements and adopting advanced analytics to predict and respond to potential disruptions before they materialize.

Unveiling Key Patient and Product Segmentation Dynamics Guiding Personalized Treatment Pathways and Distribution Strategies in Benign Prostatic Hyperplasia Care

The benign prostatic hyperplasia medication market reveals distinct patient and product segments that guide targeted strategies. When categorized by product type, therapies range from 5-alpha reductase inhibitors-such as dutasteride and finasteride-to alpha blockers including alfuzosin, doxazosin, tamsulosin, and terazosin, as well as combination therapies pairing dutasteride or finasteride with tamsulosin. Each class presents unique efficacy and safety considerations, influencing physician prescribing patterns.

Further segmentation by drug type distinguishes between branded and generic offerings, shaping cost dynamics and patient access. Distribution channels encompass hospital pharmacies, online pharmacies, and retail pharmacies, each with differing logistical requirements and customer experiences. Patient demographics add another layer of complexity: individuals aged 45 to 64 often prioritize rapid symptom relief and may opt for branded names, while those 65 and above, subsegmented into 65 to 74, 75 to 84, and 85 and above, demand simplified regimens with minimal side effects. Younger adults below 45, though representing a smaller cohort, increasingly engage with telehealth solutions for early intervention. Understanding these intersecting dimensions allows stakeholders to tailor product portfolios, pricing models, and patient support initiatives for maximum impact.

Mapping Regional Variations in Treatment Adoption Patterns and Reimbursement Models Across the Americas Europe Middle East and Asia Pacific

Regional dynamics in benign prostatic hyperplasia treatment are shaped by regulatory environments, reimbursement structures, and evolving patient expectations. In the Americas, particularly the United States, well-established reimbursement frameworks support broad access to both branded and generic therapies, while integrated healthcare networks drive adoption of combination regimens. Private payer formularies and Medicare guidelines play a central role in shaping market uptake and negotiating price concessions.

Across Europe Middle East and Africa, heterogeneity in healthcare funding models-from national health services to private insurance schemes-creates varying levels of affordability and access. Western European markets exhibit high penetration of fixed-dose combinations supported by robust clinician education programs, whereas emerging economies balance cost containment with growing demand for generics. In the Asia-Pacific region, aging populations and expanding public insurance schemes have spurred rapid growth in generic alpha blocker prescriptions. Key markets such as Japan and South Korea demonstrate a preference for innovative formulations, while Southeast Asia embraces online pharmacy solutions to improve rural patient reach.

Examining Leading Global Pharmaceutical Corporations and Emerging Innovators Shaping Competitive Dynamics in Benign Prostatic Hyperplasia Medication Development

Leading pharmaceutical companies continue to refine their benignant prostatic hyperplasia portfolios through strategic initiatives and pipeline investments. Multinational corporations such as Ferring Pharmaceuticals and Astellas Pharma maintain extensive research collaborations focused on novel 5-alpha reductase inhibitors with improved tolerability. Global stalwarts like Pfizer and Merck & Co leverage their commercial scale to secure favourable payer agreements and broaden patient engagement offerings, including digital adherence tools.

At the same time, Johnson & Johnson’s generics division and other specialty players are capitalizing on patent expirations to introduce cost-effective alternatives that expand market access. Emerging innovators are differentiating through biosensor-enabled dosing devices and clinic-based diagnostic platforms. Collaborative partnerships between established sponsors and venture-backed startups are increasingly common, reflecting a competitive landscape where agility and cross-sector expertise accelerate the development of next-generation therapies.

Strategic Recommendations for Industry Stakeholders to Optimize Clinical Outcomes Supply Chain Resilience and Market Positioning in Benign Prostatic Hyperplasia

Industry leaders should adopt a multifaceted strategy to strengthen market positions and enhance patient outcomes in benign prostatic hyperplasia care. Prioritizing supply chain diversification by engaging both domestic and international API manufacturers can reduce reliance on tariff-exposed regions and improve procurement resilience. Investing in sustained-release and combination formulations will address evolving physician and patient preferences, while partnerships with digital health providers can facilitate adherence monitoring and support value-based care models.

Moreover, aligning product portfolios with segmented pricing strategies across age groups and distribution channels will optimize revenue potential and access. Engaging in proactive dialogue with payers and regulatory agencies ensures favorable reimbursement environments for innovative therapies. Finally, fostering cross-functional collaboration between R&D, commercial, and medical affairs teams will accelerate the translation of real-world evidence into strategic insights, enabling agile responses to emerging competitive threats.

Comprehensive Research Methodology Integrating Primary Expert Interviews Secondary Data Analysis and Rigorous Triangulation to Ensure Robust Insights

This research integrates a robust combination of primary and secondary methodologies to deliver authoritative insights. Primary research was conducted through in-depth interviews with urologists, payers, procurement directors, and patient advocacy leaders, ensuring a comprehensive understanding of clinical practices, reimbursement dynamics, and patient preferences. Secondary data collection involved an extensive review of peer-reviewed journals, regulatory filings, and proprietary industry databases to capture the latest trends in drug development and therapy adoption.

Subsequent analysis applied rigorous triangulation techniques, cross-validating findings across quantitative sales data, prescription trends, and expert feedback. Segmentation analyses were performed to map product, demographic, and channel-specific characteristics, while regional assessments incorporated macroeconomic factors and healthcare policy considerations. All insights were subject to peer review and expert validation to confirm their accuracy, relevance, and strategic applicability.

Concluding Insights Summarizing Key Discoveries Critical Challenges and Strategic Imperatives Driving Future Directions in Benign Prostatic Hyperplasia Treatment

Throughout this executive summary, we have illuminated the dynamic forces driving the benign prostatic hyperplasia medication market-from technological disruptions and trade policy shifts to nuanced patient and regional segmentation patterns. Critical challenges such as tariff-induced supply chain vulnerabilities and the imperative for personalized patient engagement underscore the need for adaptive strategies. Simultaneously, the evolution of combination therapies and digital health integrations offers a blueprint for future innovation.

As the landscape continues to transform, stakeholders must maintain a holistic perspective that balances clinical efficacy, cost management, and regulatory compliance. The interplay of global company strategies, regional reimbursement frameworks, and emerging patient-centric models will define the competitive frontier. Ultimately, success hinges on the ability to translate robust market intelligence into agile decision making that anticipates change and capitalizes on new opportunities.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • 5-Alpha Reductase Inhibitors
      • Dutasteride
      • Finasteride
    • Alpha Blockers
      • Alfuzosin
      • Doxazosin
      • Tamsulosin
      • Terazosin
    • Combination Therapies
      • Dutasteride Tamsulosin
      • Finasteride Tamsulosin
  • Drug Type
    • Branded
    • Generic
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Age Group
    • 45 to 64
    • 65 and Above
      • 65 to 74
      • 75 to 84
      • 85 and Above
    • Below 45
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited
  • Astellas Pharma Inc.
  • Ferring International Center S.A.
  • Recordati S.p.A.
  • Endo International plc
  • Bayer AG

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Surge in clinical adoption of minimally invasive aquablation therapy over drug monotherapy for BPH
5.2. Rising off-label use of combination alpha blocker and 5-alpha reductase inhibitor therapies in elderly patients with moderate BPH
5.3. Increasing focus on personalized digital health platforms for remote monitoring of urinary symptoms in BPH patients
5.4. Expansion of novel plant-derived phytotherapeutic formulations targeting prostatic inflammation
5.5. Growing investment in next-generation convective radiofrequency water vapor therapy devices for BPH treatment
5.6. Development of selective androgen receptor modulators as potential alternatives to conventional BPH medications
5.7. Emergence of real-world evidence studies assessing long-term safety of prostate-specific antigen inhibitors in BPH management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Benign Prostatic Hypertrophy Medication Market, by Product Type
8.1. Introduction
8.2. 5-Alpha Reductase Inhibitors
8.2.1. Dutasteride
8.2.2. Finasteride
8.3. Alpha Blockers
8.3.1. Alfuzosin
8.3.2. Doxazosin
8.3.3. Tamsulosin
8.3.4. Terazosin
8.4. Combination Therapies
8.4.1. Dutasteride Tamsulosin
8.4.2. Finasteride Tamsulosin
9. Benign Prostatic Hypertrophy Medication Market, by Drug Type
9.1. Introduction
9.2. Branded
9.3. Generic
10. Benign Prostatic Hypertrophy Medication Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Benign Prostatic Hypertrophy Medication Market, by Age Group
11.1. Introduction
11.2. 45 to 64
11.3. 65 and Above
11.3.1. 65 to 74
11.3.2. 75 to 84
11.3.3. 85 and Above
11.4. Below 45
12. Americas Benign Prostatic Hypertrophy Medication Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Benign Prostatic Hypertrophy Medication Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Benign Prostatic Hypertrophy Medication Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. GlaxoSmithKline plc
15.3.2. Merck & Co., Inc.
15.3.3. Boehringer Ingelheim International GmbH
15.3.4. Pfizer Inc.
15.3.5. Teva Pharmaceutical Industries Limited
15.3.6. Astellas Pharma Inc.
15.3.7. Ferring International Center S.A.
15.3.8. Recordati S.p.A.
15.3.9. Endo International plc
15.3.10. Bayer AG
16. ResearchAI17. ResearchStatistics18. ResearchContacts19. ResearchArticles20. Appendix
List of Figures
FIGURE 1. BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET: RESEARCHAI
FIGURE 24. BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET: RESEARCHSTATISTICS
FIGURE 25. BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET: RESEARCHCONTACTS
FIGURE 26. BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DUTASTERIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FINASTERIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALFUZOSIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DOXAZOSIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY TAMSULOSIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY TERAZOSIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY TERAZOSIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DUTASTERIDE TAMSULOSIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DUTASTERIDE TAMSULOSIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FINASTERIDE TAMSULOSIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY FINASTERIDE TAMSULOSIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 45 TO 64, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 45 TO 64, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 TO 74, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 TO 74, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 75 TO 84, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 75 TO 84, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 85 AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 85 AND ABOVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY BELOW 45, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY BELOW 45, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 105. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 106. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 107. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 108. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 109. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 110. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 111. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 112. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 113. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 114. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 115. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 118. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 119. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2018-2024 (USD MILLION)
TABLE 120. CANADA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 122. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 123. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 126. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 127. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 128. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 129. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 130. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 131. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 134. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 135. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2018-2024 (USD MILLION)
TABLE 136. MEXICO BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2025-2030 (USD MILLION)
TABLE 203. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 204. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 205. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 208. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 209. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 210. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 211. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 212. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 213. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 216. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 217. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2018-2024 (USD MILLION)
TABLE 218. GERMANY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2025-2030 (USD MILLION)
TABLE 219. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 220. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 221. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 224. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 225. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 226. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 227. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 228. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 229. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 232. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 233. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2018-2024 (USD MILLION)
TABLE 234. FRANCE BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2025-2030 (USD MILLION)
TABLE 251. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 252. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 253. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 254. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 255. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 256. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 257. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 258. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 259. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 260. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 261. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 264. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 265. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2018-2024 (USD MILLION)
TABLE 266. ITALY BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 65 AND ABOVE, 2025-2030 (USD MILLION)
TABLE 267. SPAIN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 268. SPAIN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 269. SPAIN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. SPAIN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. SPAIN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
TABLE 272. SPAIN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY ALPHA BLOCKERS, 2025-2030 (USD MILLION)
TABLE 273. SPAIN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 274. SPAIN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 275. SPAIN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 276. SPAIN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 277. SPAIN BENIGN PROSTATIC HYPERTROPHY MEDICATION MARKET SIZE, BY DIS

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Benign Prostatic Hypertrophy Medication market report include:
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited
  • Astellas Pharma Inc.
  • Ferring International Center S.A.
  • Recordati S.p.A.
  • Endo International plc
  • Bayer AG

Related Topics

Related Reports

Drugs for Benign Prostatic hypertrophy Market Report 2025 - Product Image

Drugs for Benign Prostatic hypertrophy Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Benign Prostatic Hypertrophy Drugs Market - Global Forecast 2025-2030 - Product Image

Benign Prostatic Hypertrophy Drugs Market - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market - Global Forecast 2025-2030 - Product Image

Benign Prostatic Hyperplasia Treatment Market - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Benign Prostatic Hyperplasia (BPH) Treatment Devices and Equipment Market Report 2025 - Product Image

Benign Prostatic Hyperplasia (BPH) Treatment Devices and Equipment Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report - Product Image

Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.